Related Blog Posts
FDA Updates Antidepressant Warning Label to Include Risk of Sudden Cardiac Death
23 hours ago ago from Drug Injury Attorney Blog
As a pharmaceutical liability attorney , I was disturbed to read about a new warning of serious side effects for the antidepressant Norpramin (desipramine hydrochloride). According to a Dec. 2 article from Medscape , the FDA and drug manufacturer Sanofi-Aventis have made significant changes to the warning label on Norpramin to reflect a risk of serious heart problems in patients taking the drug. The label now advises health care professionals ...
Related contentPfizer caught in yet more science fraud: Company altered study findings for Neurontin drug
15 hours ago ago from Beyond The Curtain
(NaturalNews) Research into internal company documents has revealed that Pfizer Inc., the world's largest research-based pharmaceutical company, tampered with the results of at least 16 study reports about its epilepsy drug, Neurontin. In order to expand the market for the drug, Pfizer unlawfully removed, altered, and changed published study findings that revealed unfavorable results. Of the 20 study reports that were produced, ...
Related contentPfizer caught.. Again
13 hours ago ago from Jmbblog. The Home of the Wellness and Wealth Warrior. Rated # 1 in defending consumers rights.
Research into internal company documents has revealed that Pfizer Inc., the world's largest research-based pharmaceutical company, tampered with the results of at least 16 study reports about its epilepsy drug, Neurontin. In order to expand the market for the drug, Pfizer unlawfully removed, altered, and changed published study findings that revealed unfavorable results. Of the 20 study reports that were produced, eight of them were not ...
Related contentFDA ‘considers’ Antipsychotic drug labels warning of weight gain/diabetes. Considers? Do your job-issue the warnings.
17 hours ago ago from CCHR International
Jennifer Corbett Dooren The Wall Street Journal December 8, 2009 WASHINGTON (Dow Jones) A top Food and Drug Administration official said Tuesday the agency is considering strengthening the labels of antipsychotic drugs to warn about weight gain and diabetes amid concerns the impact could be stronger in children compared to adults. Thomas Laughren, the director of FDA's division of psychiatric products, said the agency has asked ...
Related contentDrug Reporting in the MSM - They Just Get Sillier and Sillier
11 hours ago ago from The Australian Heroin Diaries
I’m sure this article is joke. It must be because no editor could ever let this out without risking their job and reputation ... unless you work for News Corp. The article starts with dire warnings of “significant side effects” and deadly consequences but when the side effects are listed we are faced with nothing more than minimal drug reactions. Talk about a let down. Police Warn Of Dangerous BZP Passed As Ecstasy PerthNow December ...
Related contentRelated News
Pfizer, Crown to study cancers common in Asia
18 hours ago ago from Good News Now
NEW YORK -Pfizer Inc. and Crown Bioscience Inc. said Wednesday they formed partnership to develop drugs for cancers that are common in Asia. The companies did not disclose financial terms. Pfizer will make an upfront payment and fund the research, and make additional payments if Crown's drugs advance through clinical development and regulatory review. Pfizer is based in New York, and Crown is headquartered in Santa Clara, Calif., with ...
Related contentWould you pay for a risky treatment, or play it safe?
1 day ago ago from WalletPop
If it were up to you, would you take risks with your health? Or with the course of treatment you're paying for? Most likely not, according to a new study of 216 patients with arthritis and other similar diseases. The study's researchers tested patients' willingness to take a hypothetical "new" drug that carried important benefits but also a small risk of serious side effects. And when push came to shove, the study participants weren't ...
Related contentRelated Videos
Nothing to see... move along.
